{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T20:28:50Z","timestamp":1793651330394,"version":"4.5.1"},"reference-count":91,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.hoc.2026.08.008","type":"journal-article","created":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:50:35Z","timestamp":1791316235000},"page":"1071-1088","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Histone-modifying Enzymes as Therapeutic Targets in Glioma"],"prefix":"10.1016","volume":"40","author":[{"given":"Briana A.","family":"Santo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Karim","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Emerson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.hoc.2026.08.008_bib1","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of tumors of the central nervous system: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol"},{"issue":"6134","key":"10.1016\/j.hoc.2026.08.008_bib2","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1126\/science.1232245","article-title":"Inhibition of PRC2 activity by a gain-of-function H3 mutation found in pediatric glioblastoma","volume":"340","author":"Lewis","year":"2013","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.hoc.2026.08.008_bib3","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/nm.4293","article-title":"EZH2 is a potential therapeutic target for H3K27M-mutant pediatric gliomas","volume":"23","author":"Mohammad","year":"2017","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.hoc.2026.08.008_bib4","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s00401-012-0998-0","article-title":"K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas","volume":"124","author":"Khuong-Quang","year":"2012","journal-title":"Acta Neuropathol"},{"issue":"Supplement_2","key":"10.1016\/j.hoc.2026.08.008_bib5","doi-asserted-by":"crossref","first-page":"S110","DOI":"10.1093\/neuonc\/noad220","article-title":"H3 K27M-altered glioma and diffuse intrinsic pontine glioma: semi-systematic review of treatment landscape and future directions","volume":"26","author":"van den Bent","year":"2024","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.hoc.2026.08.008_bib6","doi-asserted-by":"crossref","first-page":"e113","DOI":"10.1016\/j.wneu.2023.07.001","article-title":"Prognostic indicators for H3K27M-Mutant diffuse midline glioma: a population-based retrospective surveillance, epidemiology, and end results database analysis","volume":"178","author":"Adhikari","year":"2023","journal-title":"World Neurosurg"},{"issue":"5","key":"10.1016\/j.hoc.2026.08.008_bib7","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/nrd3674","article-title":"Epigenetic protein families: a new frontier for drug discovery","volume":"11","author":"Arrowsmith","year":"2012","journal-title":"Nat Rev Drug Discov"},{"issue":"7749","key":"10.1016\/j.hoc.2026.08.008_bib8","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/s41586-019-1038-1","article-title":"The expanding landscape of \u2019oncohistone\u2019 mutations in human cancers","volume":"567","author":"Nacev","year":"2019","journal-title":"Nature"},{"issue":"43","key":"10.1016\/j.hoc.2026.08.008_bib9","doi-asserted-by":"crossref","first-page":"12238","DOI":"10.1073\/pnas.1614120113","article-title":"Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial-mesenchymal transition","volume":"113","author":"Zhao","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"10.1016\/j.hoc.2026.08.008_bib10","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1042\/BST20210567","article-title":"Histone mutations in cancer","volume":"51","author":"Espinoza","year":"2023","journal-title":"Biochem Soc Trans"},{"issue":"6291","key":"10.1016\/j.hoc.2026.08.008_bib11","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1126\/science.aae0065","article-title":"The histone H3.3K36M mutation reprograms the epigenome of chondroblastomas","volume":"352","author":"Fang","year":"2016","journal-title":"Science"},{"issue":"4139","key":"10.1016\/j.hoc.2026.08.008_bib12","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1126\/science.184.4139.868","article-title":"Chromatin structure: a repeating unit of histones and DNA","volume":"184","author":"Kornberg","year":"1974","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.hoc.2026.08.008_bib13","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1021\/cr500373h","article-title":"Nucleosome structure and function","volume":"115","author":"McGinty","year":"2015","journal-title":"Chem Rev"},{"issue":"6648","key":"10.1016\/j.hoc.2026.08.008_bib14","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/38444","article-title":"Crystal structure of the nucleosome core particle at 2.8 A resolution","volume":"389","author":"Luger","year":"1997","journal-title":"Nature"},{"issue":"5532","key":"10.1016\/j.hoc.2026.08.008_bib15","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1126\/science.1063127","article-title":"Translating the histone code","volume":"293","author":"Jenuwein","year":"2001","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.hoc.2026.08.008_bib16","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/cr.2011.22","article-title":"Regulation of chromatin by histone modifications","volume":"21","author":"Bannister","year":"2011","journal-title":"Cell Res"},{"issue":"4","key":"10.1016\/j.hoc.2026.08.008_bib17","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.cell.2007.02.005","article-title":"Chromatin modifications and their function","volume":"128","author":"Kouzarides","year":"2007","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.hoc.2026.08.008_bib18","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/nrg3173","article-title":"Histone methylation: a dynamic mark in health, disease and inheritance","volume":"13","author":"Greer","year":"2012","journal-title":"Nat Rev Genet"},{"issue":"4","key":"10.1016\/j.hoc.2026.08.008_bib19","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.molcel.2012.11.006","article-title":"Histone lysine methylation dynamics: establishment, regulation, and biological impact","volume":"48","author":"Black","year":"2012","journal-title":"Mol Cell"},{"issue":"11","key":"10.1016\/j.hoc.2026.08.008_bib20","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/nrg2218","article-title":"Histone lysine demethylases: emerging roles in development, physiology and disease","volume":"8","author":"Shi","year":"2007","journal-title":"Nat Rev Genet"},{"issue":"4","key":"10.1016\/j.hoc.2026.08.008_bib21","doi-asserted-by":"crossref","first-page":"609","DOI":"10.2217\/epi.15.9","article-title":"KDM1 histone lysine demethylases as targets for treatments of oncological and neurodegenerative disease","volume":"7","author":"Maes","year":"2015","journal-title":"Epigenomics"},{"issue":"4","key":"10.1016\/j.hoc.2026.08.008_bib22","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/nrm3931","article-title":"50 years of protein acetylation: from gene regulation to epigenetics, metabolism and beyond","volume":"16","author":"Verdin","year":"2015","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"12","key":"10.1016\/j.hoc.2026.08.008_bib23","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1038\/nsmb.2436","article-title":"Perceiving the epigenetic landscape through histone readers","volume":"19","author":"Musselman","year":"2012","journal-title":"Nat Struct Mol Biol"},{"issue":"4","key":"10.1016\/j.hoc.2026.08.008_bib24","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/cr.2011.42","article-title":"Readers of histone modifications","volume":"21","author":"Yun","year":"2011","journal-title":"Cell Res"},{"issue":"5","key":"10.1016\/j.hoc.2026.08.008_bib25","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nrd4286","article-title":"Targeting bromodomains: epigenetic readers of lysine acetylation","volume":"13","author":"Filippakopoulos","year":"2014","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"10.1016\/j.hoc.2026.08.008_bib26","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.molcel.2014.05.016","article-title":"The mechanisms behind the therapeutic activity of BET bromodomain inhibition","volume":"54","author":"Shi","year":"2014","journal-title":"Mol Cell"},{"issue":"7384","key":"10.1016\/j.hoc.2026.08.008_bib27","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/nature10833","article-title":"Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma","volume":"482","author":"Schwartzentruber","year":"2012","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.hoc.2026.08.008_bib28","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/ng.1102","article-title":"Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas","volume":"44","author":"Wu","year":"2012","journal-title":"Nat Genet"},{"issue":"4","key":"10.1016\/j.hoc.2026.08.008_bib29","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/nm.4296","article-title":"Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas","volume":"23","author":"Piunti","year":"2017","journal-title":"Nat Med"},{"issue":"10","key":"10.1016\/j.hoc.2026.08.008_bib30","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aau5935","article-title":"Multiple modes of PRC2 inhibition elicit global chromatin alterations in H3K27M pediatric glioma","volume":"4","author":"Stafford","year":"2018","journal-title":"Sci Adv"},{"issue":"5","key":"10.1016\/j.hoc.2026.08.008_bib31","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.ccr.2013.10.006","article-title":"Reduced H3K27me3 and DNA hypomethylation are major drivers of gene expression in K27M mutant pediatric high-grade gliomas","volume":"24","author":"Bender","year":"2013","journal-title":"Cancer Cell"},{"issue":"5","key":"10.1016\/j.hoc.2026.08.008_bib32","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.ccell.2019.04.004","article-title":"Pervasive H3K27 acetylation leads to ERV expression and a therapeutic vulnerability in H3K27M gliomas","volume":"35","author":"Krug","year":"2019","journal-title":"Cancer Cell"},{"issue":"13","key":"10.1016\/j.hoc.2026.08.008_bib33","doi-asserted-by":"crossref","DOI":"10.1172\/JCI174794","article-title":"BET bromodomain inhibition potentiates radiosensitivity in models of H3K27-altered diffuse midline glioma","volume":"134","author":"Watanabe","year":"2024","journal-title":"J Clin Investig"},{"issue":"1","key":"10.1016\/j.hoc.2026.08.008_bib34","article-title":"Systematic review of diffuse hemispheric glioma, H3 G34-mutant: outcomes and associated clinical factors","volume":"4","author":"Crowell","year":"2022","journal-title":"Neurooncol Adv"},{"issue":"1","key":"10.1016\/j.hoc.2026.08.008_bib35","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/s41698-025-01070-w","article-title":"A review of diffuse hemispheric glioma, H3 G34-mutant disease development, DNA repair, microenvironment, and treatments on the horizon","volume":"9","author":"Crowell","year":"2025","journal-title":"npj Precis Oncol"},{"key":"10.1016\/j.hoc.2026.08.008_bib36","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jocn.2021.09.004","article-title":"Glioblastoma with primitive neuronal component: an immunohistochemical study and review of literature","volume":"93","author":"Poyuran","year":"2021","journal-title":"J Clin Neurosci"},{"issue":"5","key":"10.1016\/j.hoc.2026.08.008_bib37","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s00401-013-1095-8","article-title":"Mutations in SETD2 and genes affecting histone H3K36 methylation target hemispheric high-grade gliomas","volume":"125","author":"Fontebasso","year":"2013","journal-title":"Acta Neuropathol"},{"issue":"1","key":"10.1016\/j.hoc.2026.08.008_bib38","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1186\/s40478-020-01092-4","article-title":"Effects of H3.3G34V mutation on genomic H3K36 and H3K27 methylation patterns in isogenic pediatric glioma cells","volume":"8","author":"Huang","year":"2020","journal-title":"Acta Neuropathol Commun"},{"issue":"22","key":"10.1016\/j.hoc.2026.08.008_bib39","doi-asserted-by":"crossref","DOI":"10.1172\/JCI154229","article-title":"H3.3-G34 mutations impair DNA repair and promote cGAS\/STING-mediated immune responses in pediatric high-grade glioma models","volume":"132","author":"Haase","year":"2022","journal-title":"J Clin Investig"},{"issue":"9","key":"10.1016\/j.hoc.2026.08.008_bib40","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrd4360","article-title":"Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders","volume":"13","author":"Falkenberg","year":"2014","journal-title":"Nat Rev Drug Discov"},{"issue":"9","key":"10.1016\/j.hoc.2026.08.008_bib41","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/nrd2133","article-title":"Anticancer activities of histone deacetylase inhibitors","volume":"5","author":"Bolden","year":"2006","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"10.1016\/j.hoc.2026.08.008_bib42","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/35106079","article-title":"Histone deacetylases and cancer: causes and therapies","volume":"1","author":"Marks","year":"2001","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"10.1016\/j.hoc.2026.08.008_bib43","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/nm.3855","article-title":"Functionally defined therapeutic targets in diffuse intrinsic pontine glioma","volume":"21","author":"Grasso","year":"2015","journal-title":"Nat Med"},{"issue":"12","key":"10.1016\/j.hoc.2026.08.008_bib44","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1093\/neuonc\/noad141","article-title":"Phase I trial of panobinostat in children with diffuse intrinsic pontine glioma: a report from the Pediatric Brain Tumor Consortium (PBTC-047)","volume":"25","author":"Monje","year":"2023","journal-title":"Neuro Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2026.08.008_bib45","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0169485","article-title":"Pre-Clinical study of panobinostat in xenograft and genetically engineered murine diffuse intrinsic pontine glioma models","volume":"12","author":"Hennika","year":"2017","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.hoc.2026.08.008_bib46","doi-asserted-by":"crossref","first-page":"288","DOI":"10.3171\/2018.2.PEDS17663","article-title":"The distribution, clearance, and brainstem toxicity of panobinostat administered by convection-enhanced delivery","volume":"22","author":"Singleton","year":"2018","journal-title":"J Neurosurg Pediatr"},{"issue":"11","key":"10.1016\/j.hoc.2026.08.008_bib47","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1093\/neuonc\/noad105","article-title":"PNOC015: repeated convection-enhanced delivery of MTX110 (aqueous panobinostat) in children with newly diagnosed diffuse intrinsic pontine glioma","volume":"25","author":"Mueller","year":"2023","journal-title":"Neuro Oncol"},{"issue":"22","key":"10.1016\/j.hoc.2026.08.008_bib48","doi-asserted-by":"crossref","first-page":"3623","DOI":"10.1200\/JCO.2009.25.9119","article-title":"Pediatric phase I trial and pharmacokinetic study of vorinostat: a children\u2019s oncology group phase I consortium report","volume":"28","author":"Fouladi","year":"2010","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.hoc.2026.08.008_bib49","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1093\/neuonc\/noab188","article-title":"Phase I\/II trial of vorinostat and radiation and maintenance vorinostat in children with diffuse intrinsic pontine glioma: a children\u2019s oncology group report","volume":"24","author":"Su","year":"2022","journal-title":"Neuro Oncol"},{"issue":"12","key":"10.1016\/j.hoc.2026.08.008_bib50","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1158\/1535-7163.MCT-23-0179","article-title":"Microtubule-targeting combined with HDAC inhibition is a novel therapeutic strategy for diffuse intrinsic pontine gliomas","volume":"22","author":"Ehteda","year":"2023","journal-title":"Mol Cancer Therapeut"},{"key":"10.1016\/j.hoc.2026.08.008_bib51","doi-asserted-by":"crossref","first-page":"RP96257","DOI":"10.7554\/eLife.96257.3","article-title":"Dual targeting of histone deacetylases and MYC as potential treatment strategy for H3-K27M pediatric gliomas","volume":"13","author":"Algranati","year":"2024","journal-title":"Elife"},{"issue":"5","key":"10.1016\/j.hoc.2026.08.008_bib52","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.31619","article-title":"Phase I study of vorinostat and temsirolimus in newly diagnosed or progressive diffuse intrinsic pontine glioma","volume":"72","author":"Stitzlein","year":"2025","journal-title":"Pediatr Blood Cancer"},{"issue":"15","key":"10.1016\/j.hoc.2026.08.008_bib53","doi-asserted-by":"crossref","first-page":"4104","DOI":"10.1158\/1078-0432.CCR-12-0055","article-title":"Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling","volume":"18","author":"Qian","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"14","key":"10.1016\/j.hoc.2026.08.008_bib54","doi-asserted-by":"crossref","first-page":"4007","DOI":"10.1158\/0008-5472.CAN-17-3691","article-title":"Dual HDAC and PI3K inhibition abrogates NF\u03baB- and FOXM1-Mediated DNA damage response to radiosensitize pediatric high-grade gliomas","volume":"78","author":"Pal","year":"2018","journal-title":"Cancer Res"},{"issue":"23","key":"10.1016\/j.hoc.2026.08.008_bib55","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.71417","article-title":"A phase 1 trial of fimepinostat in children and adolescents with relapsed and refractory solid and CNS tumors","volume":"14","author":"Shulman","year":"2025","journal-title":"Cancer Med"},{"issue":"4","key":"10.1016\/j.hoc.2026.08.008_bib56","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1158\/0008-5472.CAN-23-0394","article-title":"Fimepinostat impairs NF-\u03baB and PI3K\/AKT signaling and enhances gemcitabine efficacy in H3.3K27M-Diffuse intrinsic pontine glioma","volume":"84","author":"Wang","year":"2024","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.hoc.2026.08.008_bib57","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1093\/neuonc\/noaa249","article-title":"Optimal therapeutic targeting by HDAC inhibition in biopsy-derived treatment-na\u00efve diffuse midline glioma models","volume":"23","author":"Vitanza","year":"2021","journal-title":"Neuro Oncol"},{"issue":"15","key":"10.1016\/j.hoc.2026.08.008_bib58","doi-asserted-by":"crossref","first-page":"4262","DOI":"10.1158\/1078-0432.CCR-13-0312","article-title":"A phase I study of quisinostat (JNJ-26481585), an oral hydroxamate histone deacetylase inhibitor with evidence of target modulation and antitumor activity, in patients with advanced solid tumors","volume":"19","author":"Venugopal","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.hoc.2026.08.008_bib59","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/bjd.14427","article-title":"Phase II multicentre trial of oral quisinostat, a histone deacetylase inhibitor, in patients with previously treated stage IB-IVA mycosis fungoides\/S\u00e9zary syndrome","volume":"175","author":"Child","year":"2016","journal-title":"Br J Dermatol"},{"issue":"7","key":"10.1016\/j.hoc.2026.08.008_bib60","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.3109\/10428194.2015.1117611","article-title":"Quisinostat, bortezomib, and dexamethasone combination therapy for relapsed multiple myeloma","volume":"57","author":"Moreau","year":"2016","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"10.1016\/j.hoc.2026.08.008_bib61","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1002\/ijc.34559","article-title":"GSK-J4: an H3K27 histone demethylase inhibitor, as a potential anti-cancer agent","volume":"153","author":"Dalpatraj","year":"2023","journal-title":"Int J Cancer"},{"issue":"12","key":"10.1016\/j.hoc.2026.08.008_bib62","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1038\/nm.3716","article-title":"Pharmacologic inhibition of histone demethylation as a therapy for pediatric brainstem glioma","volume":"20","author":"Hashizume","year":"2014","journal-title":"Nat Med"},{"issue":"18","key":"10.1016\/j.hoc.2026.08.008_bib63","doi-asserted-by":"crossref","first-page":"5572","DOI":"10.1158\/1078-0432.CCR-18-3890","article-title":"Radiosensitization by histone H3 demethylase inhibition in diffuse intrinsic pontine glioma","volume":"25","author":"Katagi","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.hoc.2026.08.008_bib64","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s40265-020-01288-x","article-title":"Tazemetostat: first approval","volume":"80","author":"Hoy","year":"2020","journal-title":"Drugs"},{"issue":"11","key":"10.1016\/j.hoc.2026.08.008_bib65","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S1470-2045(20)30451-4","article-title":"Tazemetostat in advanced epithelioid sarcoma with loss of INI1\/SMARCB1: an international, open-label, phase 2 basket study","volume":"21","author":"Gounder","year":"2020","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.hoc.2026.08.008_bib66","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1016\/S1470-2045(20)30441-1","article-title":"Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial","volume":"21","author":"Morschhauser","year":"2020","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.hoc.2026.08.008_bib67","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1002\/ddr.21796","article-title":"Potential of enhancer of zeste homolog 2 inhibitors for the treatment of SWI\/SNF mutant cancers and tumor microenvironment modulation","volume":"82","author":"Pyziak","year":"2021","journal-title":"Drug Dev Res"},{"issue":"5","key":"10.1016\/j.hoc.2026.08.008_bib68","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1101\/gad.415507","article-title":"The polycomb group proteins bind throughout the INK4A-ARF locus and are disassociated in senescent cells","volume":"21","author":"Bracken","year":"2007","journal-title":"Genes Dev"},{"issue":"9","key":"10.1016\/j.hoc.2026.08.008_bib69","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1158\/1541-7786.MCR-16-0389","article-title":"Histone H3.3K27M represses","volume":"15","author":"Cordero","year":"2017","journal-title":"Mol Cancer Res"},{"issue":"Supplement_2","key":"10.1016\/j.hoc.2026.08.008_bib70","doi-asserted-by":"crossref","first-page":"S92","DOI":"10.1093\/neuonc\/noad164","article-title":"H3K27M mutant glioma: disease definition and biological underpinnings","volume":"26","author":"Saratsis","year":"2024","journal-title":"Neuro Oncol"},{"issue":"11","key":"10.1016\/j.hoc.2026.08.008_bib71","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1093\/jnci\/djad085","article-title":"Tazemetostat for tumors harboring SMARCB1\/SMARCA4 or EZH2 alterations: results from NCI-COG pediatric MATCH APEC1621C","volume":"115","author":"Chi","year":"2023","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.hoc.2026.08.008_bib72","unstructured":"Administration USFaD. FDA Alerts Health Care Providers and Patients about the Increased Risk of New Blood Cancers with Tazverik (tazemetostat) Use; Sponsor to Voluntarily Withdraw Product from Market. Available at: https:\/\/www.fda.gov\/drugs\/drug-alerts-and-statements\/fda-alerts-health-care-providers-and-patients-about-increased-risk-new-blood-cancers-tazverik (Accessed 31 July 2026)."},{"key":"10.1016\/j.hoc.2026.08.008_bib73","article-title":"EZH2 inhibition and myeloid risk: a feature of On-Target biology","volume":"14","author":"Alumkal","year":"2026","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.hoc.2026.08.008_bib74","series-title":"Tazemetostat in combination with lenalidomide and rituximab in patients with relapsed\/refractory follicular lymphoma: phase 1b results of symphony-1","author":"Batlevi","year":"2022"},{"key":"10.1016\/j.hoc.2026.08.008_bib75","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1182\/blood-2023-179910","article-title":"Tazemetostat in combination with lenalidomide and rituximab in patients with relapsed\/refractory follicular lymphoma: updated phase 1b results of symphony-1 with 22.5 months follow-up","volume":"142","author":"Salles","year":"2023","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2026.08.008_bib76","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/s41598-023-48652-x","article-title":"PRMT5 inhibition shows in vitro efficacy against H3K27M-altered diffuse midline glioma, but does not extend survival in vivo","volume":"14","author":"Brown","year":"2024","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.hoc.2026.08.008_bib77","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1158\/1541-7786.MCR-24-0233","article-title":"PRMT5 maintains tumor stem cells to promote pediatric high-grade glioma tumorigenesis","volume":"23","author":"DeSisto","year":"2025","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.hoc.2026.08.008_bib78","series-title":"A phase 1 study of the protein arginine methyltransferase 5 (PRMT5) brain-penetrant inhibitor PRT811 in patients (pts) with recurrent high-grade glioma or uveal melanoma (UM)","author":"Monga","year":"2023"},{"issue":"Supplement_5","key":"10.1016\/j.hoc.2026.08.008_bib79","doi-asserted-by":"crossref","first-page":"v422","DOI":"10.1093\/neuonc\/noaf201.1669","article-title":"TIP-09. A phase 0\/1 study of PRMT5 inhibitor BMS-986504 in recurrent glioblastoma participants with MTAP deletion","volume":"27","author":"Sanai","year":"2025","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.hoc.2026.08.008_bib80","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/978-981-15-8104-5_6","article-title":"Epigenetic-targeted treatments for H3K27M-Mutant midline gliomas","volume":"1283","author":"Lu","year":"2021","journal-title":"Adv Exp Med Biol"},{"issue":"8","key":"10.1016\/j.hoc.2026.08.008_bib81","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/s41419-020-02800-7","article-title":"Combined treatment with CBP and BET inhibitors reverses inadvertent activation of detrimental super enhancer programs in DIPG cells","volume":"11","author":"Wiese","year":"2020","journal-title":"Cell Death Dis"},{"issue":"832","key":"10.1016\/j.hoc.2026.08.008_bib82","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adr1557","article-title":"Combined inhibition of FACT and BET disrupts transcription to suppress tumor growth in mouse models of diffuse midline glioma","volume":"18","author":"Holliday","year":"2026","journal-title":"Sci Transl Med"},{"issue":"2","key":"10.1016\/j.hoc.2026.08.008_bib83","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.108994","article-title":"Dual targeting of the epigenome via FACT complex and histone deacetylase is a potent treatment strategy for DIPG","volume":"35","author":"Ehteda","year":"2021","journal-title":"Cell Rep"},{"issue":"6","key":"10.1016\/j.hoc.2026.08.008_bib84","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1093\/neuonc\/noac263","article-title":"Trotabresib, an oral potent bromodomain and extraterminal inhibitor, in patients with high-grade gliomas: a phase I, \"window-of-opportunity\" study","volume":"25","author":"Moreno","year":"2023","journal-title":"Neuro Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2026.08.008_bib85","article-title":"Trotabresib (CC-90010) in combination with adjuvant temozolomide or concomitant temozolomide plus radiotherapy in patients with newly diagnosed glioblastoma","volume":"4","author":"Vieito","year":"2022","journal-title":"Neurooncol Adv"},{"issue":"9","key":"10.1016\/j.hoc.2026.08.008_bib86","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1093\/neuonc\/noac041","article-title":"Imipridones affect tumor bioenergetics and promote cell lineage differentiation in diffuse midline gliomas","volume":"24","author":"Przystal","year":"2022","journal-title":"Neuro Oncol"},{"issue":"12","key":"10.1016\/j.hoc.2026.08.008_bib87","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.neo.2020.09.005","article-title":"ONC201 and imipridones: anti-cancer compounds with clinical efficacy","volume":"22","author":"Prabhu","year":"2020","journal-title":"Neoplasia"},{"issue":"1","key":"10.1016\/j.hoc.2026.08.008_bib88","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s40265-025-02252-3","article-title":"Dordaviprone: first approval","volume":"86","author":"Blair","year":"2026","journal-title":"Drugs"},{"issue":"11","key":"10.1016\/j.hoc.2026.08.008_bib89","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1158\/2159-8290.CD-23-0131","article-title":"Clinical efficacy of ONC201 in H3K27M-Mutant diffuse midline gliomas is driven by disruption of integrated metabolic and epigenetic pathways","volume":"13","author":"Venneti","year":"2023","journal-title":"Cancer Discov"},{"key":"10.1016\/j.hoc.2026.08.008_bib90","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2025.115695","article-title":"Drug delivery strategies for paediatric diffuse midline gliomas","volume":"226","author":"Duca","year":"2025","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.hoc.2026.08.008_bib91","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2021.742561","article-title":"Emerging advances in combinatorial treatments of epigenetically altered pediatric high-grade H3K27M gliomas","volume":"12","author":"Leszczynska","year":"2021","journal-title":"Front Genet"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858826001097?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858826001097?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T19:56:20Z","timestamp":1793649380000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858826001097"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":91,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["S0889858826001097"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2026.08.008","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Histone-modifying Enzymes as Therapeutic Targets in Glioma","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2026.08.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}